Excessive EPO Use Will Be Examined In House Ways & Means Hearing
Representatives from the Government Accountability Office, CMS and FDA are expected to testify at a Dec. 6 House Ways & Means Committee hearing on controlling utilization of Amgen's EPO products Epogen and Aranesp in dialysis facilities
You may also be interested in...
Two recently published studies may curtail aggressive elevation of hemoglobin levels with erythropoiesis-stimulating agents in anemia patients
The debate around Medicare reimbursement for Amgen's anemia treatments Aranesp and Epogen is being reopened by House Ways & Means Committee Chairman Bill Thomas (R-Calif.) as CMS drafts its annual payment update rule that addresses the issue
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.